New treatment soon?

I had the same question and from everything I have read, bronchiectasis is not a COPD disease. Here is a good article from Healthline that explains the differences between COPD and bronchiectasis. https://www.healthline.com/health/copd/bronchiectasis-copd#bronchiectasis.

COPD is given as the cause of bronchiectasis in 8.1% of 17000 patients from the European EMBARC-study
38%:no known cause
21%:post-infective
8.1: COPD
6.9%:asthma

and MAC is much rarer in Europe than USA

I had read here, Brensocatib would be probably available
end 2025

I

Hi Spider109. Yesterday I asked my pulmonologist about the Brensocatib, and he said it would be just for people with bronchiectasis but not for people who have MAC. That's a big disappointment for me because I have both, but it's also possible that he's wrong, or that the drug developers will expand the target audience, or some other such thing. Fingers crossed!

BX - airways are thickened/scared
COPD - primarily affects the air sacs
Got both, yes lung function greatly reduced

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255363/pdf/main.pdf
Chronic obstructive pulmonary disease (COPD) and bronchiectasis
are two different diseases with overlapping clinical presentation.
Patients are frequently diagnosed with both diseases,
and this is termed COPD-bronchiectasis association.
Huang et al.28 recently demonstrated that patients with COPD and
COPD- bronchiectasis association presented different profiles
in their lung microbiota and host responses.
Lung microbiota of the latter group was closer to that of bronchiectasis
patients. The authors suggested classifying patients with COPD,
bronchiectasis and COPD-bronchiectasis association into 5 different
endotypes according to their clinical, sputum microbiome and
protein profiles, which may present treatable traits.
-The first proposed endotype is the diverse-protective endotype,
which has the best prognosis.
-Second, the Haemophilus-proteolytic endotype is associated with Haemophilus
infection,for which tetracyclines could be a theoretical treatment option.
-Third, the infected-epithelial response endotype has characteristics
of bronchiectasis patients, such as gram-negative infection, and may
benefit from macrolide treatment.
-Fourth is the proteobacteria-neutrophilic endotype, in which macrolides
may also be beneficial, as this group also has similarities with
bronchiectasis and excessive neutrophil activation with the formation
of NETs.
-Finally, the Th2 endotype responds to inhaled corticosteroids (ICS) or
other treatments targeting Th2 inflammation.29

{Th2 =? T2-high : eosinophilic , high FENO}

A little over my head

The "gram negative may benefit from macrolide treatment" means Azithromycin 3 x a week treatment and pseudomonas is the gram negative.

Maybe similar in that both COPD and Bronchiectasis are chronic obstructive airway diseases?
With COPD airways become narrower I believe but with BE, small airways are permanently enlarged and mucus gets stuck in the airways — leaving us with excess mucus our bodies can’t get rid of normally and the potential for infections etc.

Yes, they are both chronic and they are both obstructive airway diseases so I am curious why BE does not fall under COPD. I am also curious what other diseases are included in the COPD umbrella. All I ever read is bronchitis and emphysema are the most common forms of COPD.

I’ve only read that you can have Bronchiectasis but not COPD. Different diagnosis but both chronic obstructive airway conditions.